论文部分内容阅读
背景:持续性雄激素抑制(continuousandrogensuppression,CAS)是目前晚期前列腺癌内分泌治疗的金标准。CAS不仅可能导致前列腺癌的雄激素依赖状态迅速丧失,使预后更差,而且可能导致生活质量下降,以及与治疗相关的副作用及费用明显增加。近年来的一些实验研究及临床观察性试验显示,间歇性雄激素抑制intermittentandrogensuppression,IAS)可(能避免或至少能够减少以上缺点。但是目前仍有争议。目的:回顾关于IAS的实验及临床研究结果,明确IAS是否为晚期前列腺癌的较为理想的治疗方式。研究选择:选择关于IAS的文献,不排除其是否为随机、盲法等论证推荐的文章。数据来源:进行全面的检索,检索手段包括电子检索、手工检索及个人通信等。数据提取:对检索到的IAS及CAS研究文章中相关信息进行综述。主要观察指标:IAS与CAS比较,可能延缓前列腺癌进展为雄激素非依赖状态,延长生存期,提高生活质量,减少副作用和治疗费用。结果:实验研究提示,周期性地进行IAS可能恢复肿瘤细胞的凋亡能力,从而延缓雄激素非依赖状态的产生;临床观察也提示IAS可能能够延缓前列腺癌进展为雄激素非依赖状态,延长生存期,提高生活质量(恢复性欲、性功能等)以及减少治疗相关的费用和副作用。2个正在进行的随机临床试验的中期分析也证实IAS较之于
BACKGROUND: Continuousandrogensuppression (CAS) is the gold standard for endocrine therapy of advanced prostate cancer. Not only does CAS cause the rapid loss of androgen dependence in prostate cancer, making the prognosis worse, it can also lead to a deterioration in quality of life and a significant increase in treatment-related side effects and costs. In recent years, some experimental studies and clinical observational studies have shown intermittent androgensuppression (IAS) can (avoid or at least reduce the above shortcomings.) However, there is still controversy.Objective: To review the results of IAS experiments and clinical studies , To determine whether IAS is an ideal treatment for advanced prostate cancer.Reselection: IAS selection literature, do not rule out whether it is random, blind law argumentation and other articles recommended.Data source: to conduct a comprehensive search, retrieval means include Electronic Retrieval, Manual Retrieval, Personal Communication, etc. DATA EXTRACTION: A review of the relevant information in the retrieved IAS and CAS research articles is provided.MAIN OUTCOME MEASURES: IAS versus CAS may delay the progression of prostate cancer to androgen-independent status and prolongation Survival, quality of life, side effects and treatment costs.Results: Experimental studies suggest that periodic IAS may restore tumor cell apoptosis, which delay the production of androgen-independent status; clinical observations also suggest that IAS may be able to Prolonged prostate cancer progression to androgen independent status, prolong survival, High quality of life of the interim analysis (restore libido, sexual function, etc.), and randomized clinical trials to reduce treatment-related side effects and costs of the ongoing .2 IAS also confirmed compared to